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Given the complexities of multimodality treatment for patients with head and neck cancer, the rationale
for the use of multidisciplinary teams (MDTs) to define individual optimal treatment strategies on a per-
patient basis is apparent. Increased use of guideline-directed approaches, reduced time to treatment and
improved outcomes, which result from use of an MDT approach in head and neck cancer, have been doc-
umented. A discussion of these recent advances, as well as presentation of available country-specific
guidance on the roles and responsibilities of team members, supports the creation of similar local-
language recommendations for the treatment of patients with head and neck cancer. Finally, expert prac-
tical advice on the implementation of MDTs may enable the establishment of the MDT approach more
universally around the world.
 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Given the complexities of multimodality treatment for patients
with cancer, no one medical professional can possess the necessary
background to make optimal treatment decisions independently or
avoid inevitable unconscious bias toward their own area of exper-
tise. In most major cancer types, multidisciplinary teams (MDTs)
were implemented previously, and, in recent years, the MDT
approach has been extended to head and neck cancer. Head and
neck cancers involve several anatomically diverse sites, including
larynx, pharynx, nasal cavity, paranasal sinuses, and oral cavity.
Both the cancer and its treatment can affect vital functions, such
as breathing and swallowing, be associated with poor functional
outcome (e.g. chewing and speech), and have profound effects on
cosmetic appearance, all of which may affect the patient’s quality
of life. The complexity of disease, the need for multimodalitytreatment, which can include surgery, radiation, chemotherapy,
and/or targeted therapy, and the patient population, which is more
likely to be elderly and have comorbidities and less social support,
argue for an individually tailored treatment plan. Furthermore,
treatment goals—which include cure, organ preservation, palliation,
and a desire to minimize toxicity, reduce symptoms, and maintain
quality of life—must also be considered. Thus, optimal management
of patients with head and neck cancer should involve a range
of healthcare professionals with relevant expertise [1]. This
review discusses the data supporting the use of MDTs for the
treatment of patients with head and neck cancer and presents
the available country-specific guidance to enable more widespread
implementation of MDTs to improve the care of patients globally.Methods
A literature search of PubMed and Google Scholar, with
the combined search terms of ‘‘head and neck cancer” and
‘‘multi-disciplinary” for the period January 1, 2000, to November 1,
2015, was performed. In addition, the websites of prominent national
and international organizations that develop English-language
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Medical Oncology (ESMO), the National Comprehensive Cancer
Network (NCCN), the New Zealand Guidelines Group, the Sociedad
Española de Oncología Médica (SEOM), and the UK National
Institute for Health and Clinical Excellence—were searched.
Guidelines and legal requirements are difficult to identify and
access, and we recognized that such guidelines would be written
in the local language. Therefore, we contacted Merck colleagues
with specific knowledge of head and neck cancer treatment in their
respective countries to request additional information regarding
the legal requirements for MDTs, the availability of guidelines,
and key supporting references for each country. Responses were
received from 29 countries.Table 1
Recommended team composition.
Teama Specialty
Core team Head and neck surgeon(s)/oral and maxillofacial surgeon(s)
Radiation oncologist
Medical oncologist
Pathologist
Radiologist ± PET-trained imaging specialist/diagnostic radiologist/nu
with PET expertise
Otolaryngologist
Dentist/oral health consultant
Maxillofacial prosthodontist
Plastic and reconstructive surgeon
Referring physician
Hematologist
Respiratory physician
Palliative medicine physician
Specialist nurse
Speech language pathologist
Dietitian
Social worker
Clinical trial coordinator
Data manager
MDT meeting coordinator/pathway project officer/administrative offi
Extended
team
Neurosurgeon
Upper GI surgeon
Thoracic surgeon
Prosthetic anaplastologist
Vascular surgeon
Anesthesiologist
Gastroenterologist
Endocrinologist
Interventional radiologist
Neurotologist
Neurosurgeon
Ophthalmologist
Psychiatrist/mental health professional
Critical care physician
Radiation physicist
Radiation therapist/therapeutic radiographer
Hyperbaric medicine
Dermatologist
Pain management specialist
Pharmacist
Addiction services
Audiology
HCP with expertise in gastrostomy placement
Palliative care
Dental hygienists/technician
Geriatric cancer assessment team
Adolescent and young adult cancer assessment team
Home care team
Physiotherapist
Occupational therapist
Rural/remote liaison nurse
Benefits advisor
AU, Australia; CA, Canada; DE, Germany; DK, Denmark; IT, Italy; MDT, multidisciplinary
UK, United Kingdom.
a IT and NZ guidelines do not distinguish between a core team and extended team. Fr
specific specialists that must be included in the MDT.Rationale for the MDT approach
In the absence of an MDT discussion, there is a real risk that fac-
tors relevant to treatment planning might be missed, and, in some
cases, patients may not be considered for the appropriate treat-
ment. Thus, the ability to individualize the optimal treatment
approach for each patient may be lost. In addition, the opportunity
to recruit to important clinical trials may be missed. As treatment
in head and neck cancer began to include a multimodality
approach, the benefits of MDTs in decision-making became appar-
ent [2]. Several governing bodies—including ESMO [3], the NCCN
[4], and SEOM [5]—recommend that treatment plans be estab-
lished by an MDT [6,7]. Similarly, a working group of Asian expertsSupported by guidelines and published references
in countries
AU, CA, DE, DK, IT, NL, NZ, UK
AU, CA, DE, IT, NL, NZ, UK
AU, CA, DE, DK, IT, NL, NZ, UK
AU, CA, DE, DK, NL (as extended team), NZ, UK
clear medicine specialist AU, CA, DE, DK, NZ, UK
IT, NZ
AU, CA, IT, NZ, UK
CA, NZ
AU, CA, DK (as extended team), NL, NZ, UK
NZ, UK
DE
AU
AU, UK
AU, CA, DK, IT, NZ, UK
CA, IT, NL (as extended team), NZ, UK
CA, IT, NL (as extended team), NZ, UK
AU, CA, IT, UK (as extended team)
AU
AU, UK
cer/care coordinator AU, DK, NZ, UK
AU, CA, DK
AU
CA
CA, NL
AU
CA, UK
UK
DK
CA
CA
NZ
AU, CA, DK, UK
AU, CA, IT, NZ, UK
CA
CA, NL
CA, NL, UK
CA
CA
AU, CA, IT, NZ, UK
CA
AU
AU
CA, NZ, UK
CA, NZ
CA, NL, UK
AU
AU, NZ
CA
CA, NL, UK
AU, CA, UK
AU
UK
team; NL, the Netherlands; NZ, New Zealand; PET, positron emission tomography;
ance is not included in the table because the French guidelines do not delineate the
Table 2
Summary of available guidelines on the establishment of MDTs.
Country or
region
Reference
Australia South Australian Head and Neck Cancer Pathway 2013
South Australian Health website: http://www.sahealth.
sa.gov.au
Austria Leitlinie des DONKO zur Erstellung einer Geschäftsordnung
für Tumorboards
DONKO website: http://donko.or.at
Alberta,
Canada
Harris JR, et al. Curr Oncol 2014;21:e704–4
Denmark Progress for Head and Neck Cancer, National Board of Health,
2012
Sundhedsstyrelsen website: https://sundhedsstyrelsen.dk
France Deneuve S et al. Eur Ann Otorhinolaryngol Head Neck Dis
2015;132: 213–5 and
HAS, ÉVALUATION ET AMÉLIORATION DES PRATIQUES, Une
démarche d’amélioration de la qualité, Réunion de
concertation pluridisciplinaire en cancérologie
Oncopaca website: http://www.oncopaca.org
Germany Erhebungsbogen Kopf-Hals-Tumorzentren in Onkologischen
Zentren
http://www.onkozert.de
Italy Associazione Italiana di Oncologia Medica (AIOM) website:
http://www.aiom.it/
Linee guida Tumori Della Testa E Del Collo 2015 and
State of the Art Oncology in Europe website: http://www.
startoncology.net and
The Italian Head and Neck Oncologic Society website:
www.AIOCC.it
Netherlands Centralization of Head and Neck Cancer Care
Netherlands Head and Neck Cancer Working Group website:
http://www.nwhht.nl/
New Zealand Standards of Service Provision for Head and Neck Cancer
Patients in New Zealand–Provisional 2013 available at the
New Zealand Ministry of Health website: https://www.
health.govt.nz
United
Kingdom
Improving Outcomes in Head and Neck Cancers. The Manual
2004
Regular updates are available at the National Institute for
Clinical Excellence website: https://www.nice.org.uk
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of MDT discussion, keeping patient preference and clinician exper-
tise in mind [8].
In the complex treatment path for patients with head and neck
cancer, multiple specialists will provide input into the treatment
plan [9]. A team approach is designed to provide all patients with
a carefully determined treatment plan focused on providing the
most comprehensive, effective care possible. This should occur
whenever a new management plan is required. Every relapse and
every decision to start a new systemic treatment should be dis-
cussed [7]. Published guidelines recommend that the MDT include
members with the skills required to deal with the full range of
patients treated by the MDT (Table 1), that all patients be discussed
by a core team, and that referrals to an expanded team of special-
ists occur depending on the needs of the patient (Table 1). How-
ever, the suggested composition of the core team varies across
guidelines. Country-specific guidelines support both smaller and
larger core-team approaches (Table 1). Most guidelines provide
specific recommendations regarding the specialists that should
be included in the core MDT (Table 1).Goals and responsibilities
Most published guidelines (Table 2) recommend that the MDT
have stated goals, which may include an increased ability to recruit
patients to clinical trials, optimized treatment planning, including
better adherence to country-specific guidelines, improved coordi-
nation between care providers and support teams, and moreefficient delivery of care. In addition, the MDT should follow
documented procedures and hold regular formal meetings, which
all members are expected to attend on a regular basis.
The role of the MDT begins at the time of the initial diagnosis
and treatment planning, when the team formulates an individual-
ized treatment approach based on the disease characteristics of the
individual patient as well as their history, health and performance
status, and treatment goals. The MDT should continue to be
involved in the management of the patient over the course of their
disease and recovery. A plan should be in place regarding when
and how to provide the initial assessment, the suitability of the
patient for relevant clinical trials, supportive care to manage treat-
ment toxicities, and the process for consideration of later treat-
ment modalities [2]. The decision to provide only best supportive
care should also be ratified by an MDT. Recommendations should
be periodically reviewed against treatment decisions to improve
decision-making for future patients, and, when there is deviation
from the MDT’s recommendation, the rationale for treatment deci-
sions should be documented [10]. The Australian guidelines rec-
ommend that patients and their primary care providers be
informed about the role of the MDT in the decision-making pro-
cess. Following a decision at the MDT meeting, the referring physi-
cian should discuss the team’s treatment recommendations with
the patient. These discussions may also include the patient’s fam-
ily, and or caregiver and should include the goals of treatment,
likely outcomes and potential side effects of treatment [11]. In
some countries (e.g. France) the patient may attend the MDTmeet-
ing. Knowing that they are receiving comprehensive care may
reduce anxiety among patients and caregivers.
MDT-based care may raise questions about medicolegal risk for
members that could result in potential barriers to implementation.
Consensus recommendations regarding the legal implications of
MDTs state that healthcare professionals who contribute to a treat-
ment recommendation within an MDT share corporate responsibil-
ity for the decisions within their area of expertise [12]. Similarly,
the associated hospitals or clinics are accountable [13]. Awareness
of their legal responsibilities should encourage an effort to fully
explore all of the member’s opinions during the meetings. Impor-
tantly, physicians who feel that their opinions are not adequately
expressed by the group decision are advised to formally record
their alternate viewpoints in the patient’s record. Finally, the rec-
ommendations suggest that every opinion that differs substantially
from the majority opinion should be presented to the patient [13].
Sidhom and Poulsen suggest that all healthcare professionals prac-
ticing within an MDT be made aware of the legal implications of
their participation [13]. However, it was determined from a survey
of a total of 136 physicians working in 18 oncology MDTs in 4 hos-
pitals in Australia that awareness of these legal implications was
low; only 48% of physicians were aware that they are legally liable
for decisions made by the MDT in Australia [14]. The vast majority
(71%) of these clinicians did not formally document their dissent
when they had important disagreements with the decision pre-
sented to the patient. A greater awareness of individual responsi-
bility while working in the team environment has the potential
to both improve outcomes for patients and limit legal liabilities.Benefits of the MDT approach
MDTs with the full range of necessary expertise and access to
state-of-the-art facilities are best positioned to provide compre-
hensive and effective care for their patients. In addition to
improved survival, theoretical benefits of the MDT approach
include improved staging accuracy, increased adherence to clinical
practice guidelines, more cost-effective care, and better communi-
cation, culminating in improved value and clinician and patient
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in patient care and outcomes is challenging partly because MDTs
are considered the standard of care in head and neck cancer; iden-
tification of a valid control group or designing a prospective trial
with a ‘‘no MDT” arm is almost impossible [15]. However, evidence
is mounting as several organizations have begun to measure these
potential benefits in robust and clinically relevant ways using
either a retrospective approach or a ‘‘before and after” study
design.
MDTs positively affect treatment decisions
The value of expert data review was recognized as early as 2002
when Loevner et al. from the University of Pennsylvania Medical
Center (Philadelphia, Pennsylvania) demonstrated the clinical
value of reinterpreting cross-sectional images of patients with
head and neck cancer, in the setting of an MDT [16]. Change in
image interpretation occurred in 41% of patients, with staging
revised in 34% of patients and discovery of previously missed sys-
temic metastases in 2 patients (1.5%) [16]. To evaluate the impact
of an MDT on treatment planning, a prospective study of 120 con-
secutive patients with newly diagnosed head and neck cancer seen
between 2009 and 2010 was performed at a single institution.
When the ‘‘preconference” diagnosis, stage, and treatment plans
were compared with the ‘‘postconference” opinion of the MDT,
more than 25% of patients had some change in tumor diagnosis,
stage, or treatment plan. Within this group, 31% had a change in
diagnosis or stage that did not result in a change in treatment,
59% had a change in their treatment plan without a change in diag-
nosis, and 9% had changes in both diagnosis and treatment. Most
frequently, treatment changes involved the addition of multi-
modality care (P = 0.0084) [17]. Similarly, clinical and follow-up
data were collected prospectively from 172 patients treated at
the Sydney Head and Neck Cancer Institute (Sydney, Australia)
between December 2011 and October 2012; pre- and post-MDT
treatment plans were compared [15]. Changes in management
were documented in 30% of patients. Among the changes, 67%
were major and involved modification of cancer treatment modal-
ity, whereas minor changes included alterations to the extent of a
treatment modality (e.g. radiation field or dose) or the addition of a
diagnostic test. Referrals by a medical or radiation oncologist were
more likely to be altered by the MDT than were those made by sur-
gical oncologists (P = 0.05) [15]. More recently, The Istituto Nazio-
nale Tumori of Milan, Italy, conducted a retrospective analysis of
781 patients who were seen between May 2007 and January
2012, 70% of whom had been referred to the cancer center for a
second opinion. Following MDT evaluation, further diagnostic
investigations were requested in about 50% of cases, diagnosis
was changed in 3% of cases, and the recommended treatment
was changed in about 10% of patients. Since most referred patients
were subsequently treated at their original centers, the evaluation
of the impact of the MDT management on patient outcomes was
not possible [18].
Kelly et al., using a different method, compared files from
patients treated between 2001 and 2008, either before or after
the introduction of an MDT at Ipswich Hospital (Ipswich, Australia)
in 2006. Retrospectively collected data for patients treated in the
pre-MDT period (n = 48) were compared with prospectively col-
lected data in the post-MDT period (n = 65). Patients treated after
the implementation of the MDT system had improved rates of
adherence to local guidelines. The time between surgery and radio-
therapy was reduced from 61 to 48 days after the implementation
of the MDT (P = 0.009). Finally, the mean hospital stay declined by
more than a week (P = 0.002), which the authors propose may
reflect reductions in the time patients wait in the hospital for the
process of diagnosis, staging, and pretreatment evaluations [19].Although improved decision-making and better adherence to
guidance regarding standard of care is an important goal of MDTs,
improving the quality of life, including limiting the decline in
speech and swallowing functions, is also of great importance. Ide-
ally, any dysfunction in swallowing and communication ability
should be assessed during a pretreatment consultation with a
speech-language pathologist (SLP), and strategies to minimize dys-
function throughout treatment should be implemented. To study
the effects of MDTs on referral patterns and compliance with treat-
ment of voice and swallowing difficulties, case documents from a
series of patients with oropharyngeal cancers treated at Johns Hop-
kins (Baltimore, MD, United States) between 2006 and 2010 were
retrospectively assessed. The 25 patients treated within the MDT
had more SLP visits than did the 93 patients treated outside the
MDT (mean = 1.8 vs 0.2, P < 0.0001). Interestingly, of the multiple
factors considered, participation in an MDT clinic was the only sig-
nificant variable associated with SLP treatment compliance [20].
MDTs reduce time to treatment
Waiting times, defined as the number of days between
histopathological diagnosis and start of treatment, affect prognosis
[21–23]. Given that a goal of MDTs is to improve patient care, it
would be important to demonstrate that providing care within
the MDT structure does not negatively affect waiting times. Patil
et al. performed a retrospective chart review comparing waiting
times for patients with newly diagnosed disease who were treated
in a 24-month period either before (n = 51) or after (n = 66) imple-
mentation of an MDT approach in 2007 at the University of Cincin-
nati Veteran’s Administration Hospital (Cincinnati, Ohio, United
States) [24]. The time from initial consultation to being seen in
the otolaryngology clinic decreased significantly from 27.5 to
16.5 days (P < 0.0001), and the time from a positive biopsy result
being reported to the date of initiating definitive treatment
decreased significantly from 35 to 27 days (P = 0.04) [24]. Authors
from Charing Cross Hospital (London, United Kingdom) performed
a retrospective case-control study of the most recent 50 patients
treated without delay and compared them with the most recent
50 patients whose treatment was significantly delayed. A signifi-
cant association between initial review by a physician outside
the head and neck MDT and treatment delay was seen (P < 0.001)
[25].
MDTs can improve outcomes
Although effects on outcome are more difficult to measure than
changes to treatment patterns, evidence is accumulating that
MDTs can improve overall survival in patients with head and neck
cancer. This should not be surprising given the documented
improvements in practice that occur when MDTs are used. The first
demonstration of an impact of MDTs on survival in patients with
head and neck cancer was seen by analyzing patients in England
treated between December 1996 and November 1997 (South and
West Audit of Head and Neck Cancer; SWAHN I) and between
September 1999 and August 2000 (SWAHN II). SWAHN I demon-
strated a trend toward increased survival for patients treated by
an MDT, which was confirmed by a statistically significant
improvement in survival in the later SWAHN II cohort (hazard ratio
[HR] = 0.7, P = 0.02) [26]. Implementation of the MDT approach at
the Cincinnati Veteran’s Administration Hospital (Cincinnati, Ohio,
United States) resulted in a numerically improved 5-year mortality
rate in patients with head and neck cancer, as shown by a retro-
spective chart review [24]. Friedland et al. (University of Western
Australia, Perth, Western Australia, Australia) compared the out-
comes of 726 patients with head and neck cancer managed at a sin-
gle institution between 1996 and 2008 who were either treated
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spective analysis, patients with stage IV disease treated by an MDT
had significantly improved 5-year survival rates compared with
non-MDT–treated patients (HR = 0.69, P = 0.004) [27]. One of the
largest studies conducted in head and neck cancer involved 9297
patients with newly diagnosed oral cavity cancer treated in Tai-
wan, China. Patients who had been treated within the framework
of an MDT were matched to patients treated without MDT care.
MDT care reduced the relative risk of death (HR = 0.84, 95% CI
0.78–0.90), with stronger effects seen in older patients [28].MDTs can be run efficiently
The potential impact on cost and time may cause some clini-
cians to argue that MDTs are not practical for all patients and
should be reserved for patients with advanced disease or complex
presentations. To address such questions, an analysis of time taken
to discuss new patients with head and neck cancer in MDT meet-
ings was undertaken at Aintree University Hospital (Liverpool, Uni-
ted Kingdom) [29]. In a series of 10 weekly meetings wherein 105
patients were discussed, total time per patient ranged from 0.25 to
8 min, with a mean of 2 min. An increase in the number of MDT
participants was associated with longer discussion time (Spearman
rank-order coefficient = 0.63, P < 0.001). The longest discussions
concerned patients with advanced T (P = 0.006) and N (P = 0.009)
stage disease, the elderly (P = 0.02), and male patients (P = 0.05).
The authors commented that many patients are discussed only
briefly and that concentrating resources on patients with complex
needs who require multimodal treatment might be a good
approach. For example, early-stage patients could be registered
but only briefly discussed by the MDT. Finally, telemedicine has
been explored as an alternative to face-to-face meetings of the
MDT. In one study, patients who had attended the meetings with
their local otolaryngologist via teleconference did not experience
telemedicine as a barrier and were confident to take part in these
meetings in a familiar environment [30].Costs associated with MDT implementation
An important question for clinicians and clinic administrators is
the cost associated with running an MDT. The authors of the Aus-
tralian pre- and post-MDT prospective comparison study described
above proposed that any administrative costs associated with set-
ting up the MDT at their institution could be offset by reductions in
hospital stays and other cost savings associated with improved
patient evaluation, but they did not provide a cost analysis in their
article [19]. We researched this topic in the literature and found
very few studies that address the topic of costs. It appears that this
is a gap in our knowledge, because very little research has been
done to directly assess the costs of MDT implementation and
administration in comparison with the potential costs savings that
might arise from more efficient and effective care delivery. The
concept of value does not appear to have been addressed in the lit-
erature as of yet. In fact, a systematic literature analysis of eco-
nomic studies of MDTs used in cancer care determined that the
current evidence is insufficient to determine whether MDTs are
cost-effective [31].Authors’ perspective on implementing an MDT
Each of the authors (with the exception of PC) currently works
within an MDT and has extensive experience with MDT design,
organization, and implementation. Their collective experience
regarding the perceived benefits to patients and clinicians, as wellas the hurdles that had to be overcome to implement the MDT
approach, is presented in Table 3.
Country-specific approaches to guidance on MDTs
Responders to the Merck survey supplied feedback on the situ-
ation in a total of 29 countries in Europe, Latin America, and Asia.
The results suggest that, in many countries, MDTs are in use in
large urban academic hospital settings but are less available in
rural areas. In some countries, MDTs are required for reimburse-
ment of some specific treatment regimens (Korea and Lithuania).
Most reported that guidelines for MDT implementation are not
yet available in their country. Countries that provided guidance
include Australia, Canada, Denmark, Germany, Italy, the Nether-
lands, New Zealand, and the United Kingdom (Table 2). Countries
with legal requirements are few. Although our survey indicated
that MDTs are legally binding in Austria, Denmark, France, Korea,
and Lithuania, France was the only country for which we could
identify publically available information regarding the law.
Many guidelines specify the composition of both a core team
and an extended team (Table 2). A wide range of specialties is rep-
resented: as many as 15 core-team specialists are recommended in
the UK guidelines, and as few as 3 clinicians are recommended in
the French guidelines. To highlight the various approaches to gov-
erning the implementation of MDTs, we highlighted the
approaches adopted by 4 countries: France, Germany, Canada,
and the United Kingdom.
Canada
Although most guidelines state that all MDT members should
have specific knowledge on head and neck cancer, the Canadian
guidelines provide additional details that include recommenda-
tions for the required education level, fellowships, practice hours,
specialist certification, and minimum treatment volume for all
core-team members. The recommended core team comprises a
large number of specialties, including several that would be
included only in the extended team in other countries (Table 1).
The Canadian guidelines also include the specification of imaging
equipment, pathology testing, chemotherapy and pharmacy
requirements, radiation technologies, and speech and language
rehabilitation facilities [32].
France
MDT meetings were made mandatory in France by the Health
Ministry, as stated in the ‘‘circulaire of February 22nd, 2005,”
which outlines the legally binding quality requirements for an
MDT. At least 3 physicians of different specialties are legally
required, and, if the 3 specialists are not present, the meeting is
not quorate and the decision is not considered valid. The 3 manda-
tory specialists are the ENT (ear, nose, and throat) surgeon, medical
oncologist, and radiotherapist. Most teams also include a radiolo-
gist. The document notes that it is often preferable to have more
specialties represented. All new cases must be presented to the
MDT before treatment begins, and all modifications to treatment
should be discussed. The opinion of the MDT, including the thera-
peutic plan and the name and qualifications of the participants, are
recorded and archived in the patient file. If the treatment provided
is different from what the MDT proposed, the physician must
record the reasons for the departure from the plan [10].
Germany
The German Cancer Society has had certified centers of oncolog-
ical care since 2003 [33], and the concept of the MDT is an impor-
tant part of their approach. The process for tumor center
certification is stated in the interdisciplinary guidelines of the
German Cancer Society. To be certified as a head and neck cancer
Table 3
Authors’ perspective on implementing an MDT.
What was the impetus for setting up an MDT at your institution?
 MDTs at the authors’ institutions were developed to provide the best clinical management decisions in a very rapidly evolving treatment scenario, ensuring the best
results for patients. The MDT enables clinicians to discuss treatment strategies for difficult cases directly among different specialists, improves the ability to tailor
treatment to the individual patient, and provides a learning environment for younger clinicians
 The MDT is a fundamental part of the Functional Unit approach in Spain, wherein all patients with head and neck cancer are seen by a team of specialists at the
same time and place. Similarly, MDTs have been developed as part of a Comprehensive Cancer Center approach to improve clinical care, treatment planning, and
clinical trial participation as well as to improve and to make head and neck cancer research a priority
 The MDT approach is a legal requirement in the United Kingdom and is subject to regular cycles of external peer review. Understanding the importance of the
success of the MDT and the role of allied healthcare professionals—clinical nurse specialists, speech and language therapists, dietitians, and physical/occupational
therapists—has given impetus to inclusion of these disciplines as core members of the MDT
What has been the main benefit to patients?
 A full team of allied healthcare professionals with access to appropriate diagnostic and therapeutic equipment provides a holistic treatment plan based on scientific
evidence and adapted to the individual patient
 The time from first visit to diagnosis and to treatment can be shorter for patients who are seen by a well-organized MDT
 Patient and family satisfaction increase when they are immersed in a good organization
 Patients receive increased discussion of treatment options and access to innovative clinical trials
 Patients may trust a proposed treatment based on the collective recommendation of the MDT without the need to request a second opinion
What has been the main benefit to clinicians?
 Information is shared quickly and easily, and communication between specialists is improved. Clinicians can focus on their specialties and not have to manage
issues outside of their competence, resulting in increased professional satisfaction
 MDT meetings provide a continuous learning environment that improves the training of fellows and the overall competence of the team; sharing of experience is
especially helpful for difficult cases whereby team members can learn from their colleagues
 The experience of shared responsibility, knowledge, and skills for the care of patients with a difficult-to-treat disease gives reassurance to the clinician; sharing of
the final treatment outcome for interesting cases aids learning
 The newest treatments and protocols can be discussed and proposed to our patients
 The organization decreases the inappropriate consumption of health resources
 The implementation of an MDT approach may improve patient recruitment to trials
How long did it take to set up the MDT?
 MDTs were designed and implemented at the authors’ institutions over a range of time frames. Once all departments have made the decision to organize the MDT,
the plan can be operative in as few as 3 months. On average, it took 2 years to fully implement the MDT at the authors’ institutions
What factors were key to implementation?
 Institutional leadership is key, and the departments involved in the MDT must be in agreement. Once this has been achieved, the hospital must provide the nec-
essary rules, guidelines, and structure. In addition, hospital management should have the MDT as a goal in their strategic plan
 The legal framework and the threat of removing patient referrals from institutes that did not run properly convened MDTs provided an impetus
 Successful MDTs in other cancers, especially gastrointestinal and breast cancers, served as excellent examples
What, if any, roadblocks did you face and how did you overcome them?
 The main roadblock was to change the clinician’s mentality from one of owning the decision to a process of collective decision-making, relying on the opinion of
multiple therapeutic departments. At one institution, specialists were encouraged to make an accurate database of their cases, which became available for all physi-
cians on the MDT. This exercise made many more comfortable with the process of case discussion. At other institutions, modeling their team on successful MDTs in
other cancer types immediately removed this roadblock
 The time required for weekly meetings was considered a major roadblock. An agreement to quickly discuss relatively simple cases and spend more time on difficult
cases helped to resolve this issue
 Lack of motivation or functional rules and the need to have a common schedule and a room dedicated for an MDT were also noted as hurdles to be overcome
78 L. Licitra et al. / Oral Oncology 59 (2016) 73–79center, the site must meet requirements regarding the number of
patients seen, and tumor board meetings need to take place at least
once per week with a team consisting of a head and neck surgeon,
an oralmaxillofacial surgeon, a diagnostic radiologist, a pathologist,
a radiation oncologist, a hematologist, and an oncologist. Additional
specialists can be invited on an as-needed basis. The MDT decides
on the initial treatment plan and determines potential follow-up
therapy after completion of the primary therapy [34].United Kingdom
Similarly, the recommended core team in the United Kingdom
includes many specialists (Table 1) and advises on the core compe-
tencies of the team members and facilities. Specifically, surgery
should normally be carried out in a hospital with a specialized
head and neck unit by surgeons who dedicate at least half of their
time to head and neck cancer and treat a minimum of 100 new
cases of head and neck cancer per year. MDTs should be located
in large well-resourced centers [7]. The UK system requires regular
cycles of external and internal audits to ensure that MDTs are com-
posed of the required groups of clinicians/allied healthcare profes-
sionals. The decision-making process is also scrutinized to ensure
that decisions are being made in a consistent fashion and that they
comply with generally accepted standards of care.Conclusions
The MDT approach has been successfully implemented in a
number of countries where it is now considered the standard of
care for diagnosis, staging, treatment planning, and patient man-
agement in head and neck cancers. Given the documented
improvements in the use of guideline-directed approaches,
reduced time to treatment, and improved outcomes that result
from the use of an MDT, global implementation of the approach
has the capacity to improve the lives of patients with head and
neck cancer. Making country-specific (local language) guidelines
on the structure and function of MDTs more available should help
advance this call to action.
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